Vincenzo Salamone

Vincenzo Salamone

Auto-generated profile, based on publicly available information

Vincenzo Salamone

Department of Urology “AOU Careggi” – University of Florence Florence Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2004 in IEEE Transactions on Nuclear Science
Verified
Journal Article
Closed access
GCGiuseppe Pablo Cirrone
Giuseppe Pablo Cirrone
GCGiacomo Cuttone
Giacomo Cuttone
PLP.A. Lojacono
P.A. Lojacono
SNS. Lo Nigro
S. Lo Nigro
VMV. Mongelli
V. Mongelli
LVL.M. Valastro
L.M. Valastro
At the Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud (INFN-LNS) in Catania, Italy, the first Italian protontherapy facility, named Centro di AdroTerapia e Applicazioni Nucleari Avanzate (CATANA) has been built in collaboration with the University of Catania. It is based on the use of the 62-MeV proton beam delivered by the K=800 Superconducting Cyclotron installed and working at INFN-LNS since 1995. The facility is mainly devoted to the treatment of ocular diseases like uveal melanoma. A beam treatment line in air has been assembled together with a dedicated positioning patient system. The facility has been in operation since the beginning of 2002 and 66 patients have been successfully treated up to now. The main features of CATANA together with the clinical and dosimetric features will be extensively described; particularly, the proton beam line, that has been entirely built at LNS, with all its elements, the experimental transversal and depth dose distributions of the 62-MeV proton beam obtained for a final collimator of 25-mm diameter and the experimental depth dose distributions of a modulated proton beam obtained for the same final collimator. Finally, the clinical results over 1 yr of treatments, describing the features of the treated diseases will be reported.

21 July 2011 in The European Physical Journal Plus
Verified
Journal Article
Closed access
PDF file
GCGiacomo Cuttone
Giacomo Cuttone
GCGiuseppe Pablo Cirrone
Giuseppe Pablo Cirrone
GFG. Di Franco
G. Di Franco
VMV. La Monaca
V. La Monaca
SNS. Lo Nigro
S. Lo Nigro
LVL. M. Valastro
L. M. Valastro

19 September 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
GCGiuseppe Pablo Cirrone
Giuseppe Pablo Cirrone
GCGiacomo Cuttone
Giacomo Cuttone
LRLuigi Raffaele
Luigi Raffaele
VSVincenzo Salamone
Vincenzo Salamone
TATeresio Avitabile
Teresio Avitabile
LVLucia M. Valastro
Lucia M. Valastro
The CATANA protontherapy center was the first Italian clinical facility making use of energetic (62 MeV) proton beams for the radiative treatment of solid tumours. Since the date of the first patient treatment in 2002, 400 patients have been successful treated whose majority was affected by choroidal and iris melanomas. In this paper we report on the actual clinical and physical status of the CATANA facility describing the last dosimetric studies and reporting on the last patient follow-up results. The last part of the paper is dedicated to the description of the INFN ongoing activities on the realisation of a beamline for the transport of laser-accelerated ion beams. The ELIMED (ELI-BEamlines MEDical and multidisciplinary applications) project is intruded and its main scientific aspects described.

1 September 2003 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
CSCorrado Spatola
Corrado Spatola
GPGiuseppe Privitera
Giuseppe Privitera
LRLuigi Raffaele
Luigi Raffaele
VSVincenzo Salamone
Vincenzo Salamone
GCGiacomo Cuttone
Giacomo Cuttone
SNSalvatore Lo Nigro
Salvatore Lo Nigro
Background: The first Italian proton therapy facility was realized in Catania, at the INFN-LNS. With its energy (62 MeV proton beam), it is ideal for the treatment of shallow tumors like those of the ocular region: uveal melanoma, first of all (the most common primary intraocular malignancy of adults) and other less frequent lesions like choroidal hemangioma, conjunctiva melanoma, and eyelid tumors. Material and methods: The first patient was enrolled in February 2002, and to date 30 patients have been treated. All patients had a localized uveal melanoma, with no systemic metastases, and had specific indications for proton beam radiation therapy: lesions between 5–25 mm basal diameter, not exceeding 15 mm thickness, absence of total retinal detachment or glaucoma. According to the tumor dimensions, 2 patients had a small lesion or T1 (6%), 3 had a medium-sized lesion or T2 (10%), 14 had a large lesion or T3 (47%), and 11 had an extra-large lesion or T3 (37%); no patient had extrascleral invasion or T4 of the TNM-AJCC Staging System. In most cases, the tumor infiltrated only the choroid (14 patients, 47%) or the choroid plus the ciliary body (14 patients, 47%). We also treated a primitive iris melanoma, without diffusion to the ciliary body. The target volume was defined as the tumor plus a safety margin of 2.5 mm, laterally and antero-posteriorly; this margin was increased to 3 mm if ciliary body involvement was present. The treatment was carried out in 4 fractions on 4 consecutive days to a total dose of 54.5 Gy (single fraction 13.6 Gy), which corresponds to 60 CGE (Cobalt Gray Equivalent; single fraction 15 CGE), because the relative biological effectiveness is 1.1. Results: The first follow-up is planned at 6–8 months after the end of the treatment, and our clinical end points are local control (defined as cessation of growth or tumor shrinkage), eye retention, and maintenance of a good visual function. At the time of this writing, we had preliminary results from 13 patients. Nine patients showed tumor shrinkage (69%), 3 a substantially stable dimension (23%), but almost all patients presented an increased ultrasound reflectivity (a surrogate for tumor control). Discussion and conclusions: The literature data show that charged particle therapy has allowed an optimal local control in the treatment of uveal melanomas (about 96% in the different series, superior to that obtained with plaquetherapy [between 83% and 92%]), a metastatic rate slightly better than enucleation reports, and a survival rate of almost 90% at 5 years. Our preliminary results show a tumor response in almost all cases, with no major acute or subacute side effects. We thus plan to continue with our treatment procedures and our dose prescription.

1 January 2006 in Physica Medica
Verified
Journal Article
Closed access
GCGiuseppe Pablo Cirrone
Giuseppe Pablo Cirrone
GCGiacomo Cuttone
Giacomo Cuttone
PLPietro A. Lojacono
Pietro A. Lojacono
SNSalvatore Lo Nigro
Salvatore Lo Nigro
IPIolanda V. Patti
Iolanda V. Patti
LVLucia M. Valastro
Lucia M. Valastro

1 October 2007 in Nuclear Physics B - Proceedings Supplements
Verified
Journal Article
Closed access
GCGiuseppe Pablo Cirrone
Giuseppe Pablo Cirrone
GCGiacomo Cuttone
Giacomo Cuttone
FRF. Di Rosa
F. Di Rosa
Giorgio RussoGiorgio Russo
Giorgio Russo
VSV. Salamone
V. Salamone